Mesoblast to Present at Upcoming Global Life Sciences Conference in London
April 05 2019 - 6:00AM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular
medicines for inflammatory diseases, today announced an upcoming
corporate presentation by the company at the H.C. Wainwright Global
Life Sciences 2019 conference being held in London. The
presentation is scheduled for Monday, April 8, 2019 at 11:50am GMT.
About MesoblastMesoblast
Limited (Nasdaq:MESO; ASX:MSB) has leveraged its proprietary
technology platform to establish a broad portfolio of late-stage
allogeneic (off-the-shelf) product candidates with three product
candidates in Phase 3 trials – acute graft versus host disease,
chronic heart failure and chronic low back pain due to degenerative
disc disease. Through a proprietary process, Mesoblast selects rare
mesenchymal lineage precursor and stem cells from the bone marrow
of healthy adults and creates master cell banks, which can be
industrially expanded to produce thousands of doses from each donor
that meet stringent release criteria, have lot to lot consistency,
and can be used off-the-shelf without the need for tissue matching.
Mesoblast has facilities in Melbourne, New York, Singapore and
Texas and is listed on the Australian Securities Exchange (MSB) and
on the Nasdaq (MESO). www.mesoblast.com
For further information, please contact:
Julie Meldrum |
Schond Greenway |
Corporate Communications |
Investor Relations |
T: +61 3 9639 6036 |
T: +1 212 880 2060 |
E: julie.meldrum@mesoblast.com |
E: schond.greenway@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024